The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2015

Filed:

Mar. 15, 2013
Applicant:

Biogen Idec MA Inc., Cambridge, MA (US);

Inventors:

Sha Mi, Belmont, MA (US);

R. Blake Pepinsky, Arlington, MA (US);

Zhaohui Shao, Brookline, MA (US);

Christilyn Graff, Cambridge, MA (US);

Assignee:

Biogen MA Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 35/30 (2006.01); A61K 47/48 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 47/48538 (2013.01); A61K 2039/505 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 2316/96 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C12N 15/1138 (2013.01); C12N 2310/111 (2013.01); C12N 2310/14 (2013.01); C07K 16/28 (2013.01); A61K 47/48684 (2013.01);
Abstract

Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.


Find Patent Forward Citations

Loading…